"Authorized" Generics' Short-Term Benefits Outweighed By Drag On ANDAs, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Although authorized generics may stimulate competition, they undermine the incentive to submit generic drug applications, GPhA maintains. Association will "keep our options open" in determining "next steps."